Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on Jan. 23)
- Baudax Bio Inc (NASDAQ: BXRX)
- Mesoblast limited (NASDAQ: MESO)
- Nevro Corp (NYSE: NVRO)
- Oyster Point Pharma Inc (NASDAQ: OYST)
- Soligenix, Inc. (NASDAQ: SNGX)
- Syneos Health Inc (NASDAQ: SYNH)
- TELA Bio Inc (NASDAQ: TELA)
- Trillium Therapeutics Inc (NASDAQ: TRIL)
- Y-mAbs Therapeutics, Inc (NASDAQ: YMAB)
- Zai Lab Ltd (NASDAQ: ZLAB)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Jan. 23)
- Avanos Medical Inc (NYSE: AVNS)
- Blueprint Medicines Corp (NASDAQ: BPMC)
- Enanta Pharmaceuticals Inc (NASDAQ: ENTA)
- Evolus Inc (NASDAQ: EOLS)
- Kura Oncology Inc (NASDAQ: KURA)
- Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)
- Second Sight Medical Products Inc (NASDAQ: EYES)
- Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
- Therapix Biosciences Ltd – ADR (NASDAQ: TRPX)
Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020
Stocks In Focus
Kura Oncology Announces Departure of Chief Medical Officer
Kura Oncology said Antonio Gualberto, serving as Head of Development and Chief Medical Officer, will leave to pursue other opportunities. The company named Bridget Martell, EVP, Clinical Development, as acting Chief Medical Officer.
The stock slipped 2.12% to $12.01 in after-hours trading.
Epizyme's Epithelioid Sarcoma Drug Approved
Epizyme Inc (NASDAQ: EPZM) said the FDA has granted accelerated approved for its Tazverik, or tazemetostat, for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Continued approval is contingent upon verification of clinical benefit in a confirmatory trial.
The stock slipped 1.76% to $26.25 in after-hours trading.
Roche Tecentriq Flunks Late-Stage Study In Urothelial Cancer
Roche Holdings AG Basel ADR (OTC: RHHBY) said a Phase 3 study that evaluated its Tecentriq as an adjuvant monotherapy after surgery for muscle-invasive urothelial cancer did not meet the primary endpoint of disease-free-survival.
Sonoma to Explore Strategic Options For US Dermatology Business
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has commenced a process to explore and evaluate strategic alternatives for its U.S. Dermatology Division. Maxim Group has been engaged to assist in this process, the company added.
"We look forward to working with Maxim to develop a strategy to maximize the value of this portfolio for our shareholders," said CEO Amy Trombly.
The shares rallied 27.27% to $6.31 in after-hours trading.
Intuitive Surgical Q4 Results Exceed Expectations
Intuitive Surgical, Inc.'s (NASDAQ: ISRG) fourth-quarter revenues climbed 22% to $1.28 billion, thanks to strong procedures and systems placements. The non-GAAP net income rose from $2.96 per share to $3.48 per share. The results exceeded estimates.
The stock shed 2.60% to $599 in after-hours trading.
Applied Therapeutics Inc (NASDAQ: APLT) priced its upsized public offering of 2.74 million shares at $45.50 per share, with the offering expected to generate gross proceeds of $124.7 million. Previously, the company planned to offer 1.75 million shares.
The stock slipped 1.02% to $48.35 in after-hours trading.
The FDA will announce its verdict on Merck & Co., Inc.'s (NYSE: MRK) NDA and sNDA for DIFICID (fidaxomicin) to treat Clostridium difficile infections. The NDA pertains to an oral suspension formulation and the sNDA is for the expansion of the indication to treat children, ages six and older. Dificid, in tablet formulation, has already been approved to treat Clostridium difficile infections in adults 18 years and older.
ASCO Gastrointestinal Cancers Symposium Presentations
Bellicum Pharmaceuticals Inc (NASDAQ: BLCM): Phase 1 Cohort 5B new translational data for its pancreatic cancer experimental drug BPX-601